Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers.


Journal

Molecular neurodegeneration
ISSN: 1750-1326
Titre abrégé: Mol Neurodegener
Pays: England
ID NLM: 101266600

Informations de publication

Date de publication:
30 01 2020
Historique:
received: 29 10 2019
accepted: 14 01 2020
entrez: 1 2 2020
pubmed: 1 2 2020
medline: 20 3 2021
Statut: epublish

Résumé

A repeat expansion in the C9orf72-SMCR8 complex subunit (C9orf72) is the most common genetic cause of two debilitating neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Currently, much remains unknown about which variables may modify these diseases. We sought to investigate associations between C9orf72 promoter methylation, RNA expression levels, and repeat length, their potential effects on disease features, as well as changes over time and within families. All samples were obtained through the ALS Center at Mayo Clinic Florida. Our primary cohort included 75 unrelated patients with an expanded C9orf72 repeat, 33 patients who did not possess this expansion, and 20 control subjects without neurodegenerative diseases. Additionally, 67 members from 17 independent C9orf72 families were selected of whom 33 harbored this expansion. Longitudinally collected samples were available for 35 C9orf72 expansion carriers. To increase our understanding of C9orf72-related diseases, we performed quantitative methylation-sensitive restriction enzyme-based assays, digital molecular barcoding, quantitative real-time PCR, and Southern blotting. In our primary cohort, higher methylation levels were observed in patients with a C9orf72 repeat expansion than in patients without this expansion (p = 1.7e-13) or in control subjects (p = 3.3e-07). Moreover, we discovered that an increase in methylation levels was associated with a decrease in total C9orf72 transcript levels (p = 5.5e-05). These findings aligned with our observation that C9orf72 expansion carriers had lower expression levels of total C9orf72 transcripts than patients lacking this expansion (p = 3.7e-07) or control subjects (p = 9.1e-05). We also detected an elevation of transcripts containing intron 1a (upstream of the repeat) in patients carrying a C9orf72 repeat expansion compared to (disease) controls (p ≤ 0.01), an indication of abortive transcripts and/or a switch in transcription start site usage. While methylation and expression levels were relatively stable over time, fluctuations were seen in repeat length. Interestingly, contractions occurred frequently in parent-offspring transmissions (> 50%), especially in paternal transmissions. Furthermore, smaller repeat lengths were detected in currently unaffected individuals than in affected individuals (p = 8.9e-04) and they were associated with an earlier age at collection (p = 0.008). In blood from C9orf72 expansion carriers, we found elevated methylation levels, reduced expression levels, and unstable expansions that tend to contract in successive generations, arguing against anticipation.

Sections du résumé

BACKGROUND
A repeat expansion in the C9orf72-SMCR8 complex subunit (C9orf72) is the most common genetic cause of two debilitating neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Currently, much remains unknown about which variables may modify these diseases. We sought to investigate associations between C9orf72 promoter methylation, RNA expression levels, and repeat length, their potential effects on disease features, as well as changes over time and within families.
METHODS
All samples were obtained through the ALS Center at Mayo Clinic Florida. Our primary cohort included 75 unrelated patients with an expanded C9orf72 repeat, 33 patients who did not possess this expansion, and 20 control subjects without neurodegenerative diseases. Additionally, 67 members from 17 independent C9orf72 families were selected of whom 33 harbored this expansion. Longitudinally collected samples were available for 35 C9orf72 expansion carriers. To increase our understanding of C9orf72-related diseases, we performed quantitative methylation-sensitive restriction enzyme-based assays, digital molecular barcoding, quantitative real-time PCR, and Southern blotting.
RESULTS
In our primary cohort, higher methylation levels were observed in patients with a C9orf72 repeat expansion than in patients without this expansion (p = 1.7e-13) or in control subjects (p = 3.3e-07). Moreover, we discovered that an increase in methylation levels was associated with a decrease in total C9orf72 transcript levels (p = 5.5e-05). These findings aligned with our observation that C9orf72 expansion carriers had lower expression levels of total C9orf72 transcripts than patients lacking this expansion (p = 3.7e-07) or control subjects (p = 9.1e-05). We also detected an elevation of transcripts containing intron 1a (upstream of the repeat) in patients carrying a C9orf72 repeat expansion compared to (disease) controls (p ≤ 0.01), an indication of abortive transcripts and/or a switch in transcription start site usage. While methylation and expression levels were relatively stable over time, fluctuations were seen in repeat length. Interestingly, contractions occurred frequently in parent-offspring transmissions (> 50%), especially in paternal transmissions. Furthermore, smaller repeat lengths were detected in currently unaffected individuals than in affected individuals (p = 8.9e-04) and they were associated with an earlier age at collection (p = 0.008).
CONCLUSIONS
In blood from C9orf72 expansion carriers, we found elevated methylation levels, reduced expression levels, and unstable expansions that tend to contract in successive generations, arguing against anticipation.

Identifiants

pubmed: 32000838
doi: 10.1186/s13024-020-0359-8
pii: 10.1186/s13024-020-0359-8
pmc: PMC6993399
doi:

Substances chimiques

C9orf72 Protein 0
C9orf72 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7

Subventions

Organisme : NINDS NIH HHS
ID : R35 NS097273
Pays : United States
Organisme : NIH HHS
ID : P01 NS084974
Pays : United States
Organisme : NINDS NIH HHS
ID : R35 NS097261
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS099631
Pays : United States
Organisme : NIH HHS
ID : R35 NS097273
Pays : United States
Organisme : NINDS NIH HHS
ID : P01 NS084974
Pays : United States
Organisme : NIH HHS
ID : P01 NS099114
Pays : United States
Organisme : NIH HHS
ID : R35 NS097261
Pays : United States
Organisme : NIH HHS
ID : R21 NS099631
Pays : United States

Références

Neuron. 2011 Oct 20;72(2):257-68
pubmed: 21944779
Acta Neuropathol Commun. 2016 Apr 14;4(1):37
pubmed: 27079381
Acta Neuropathol. 2015 Sep;130(3):363-72
pubmed: 26022924
Nature. 2014 Mar 13;507(7491):195-200
pubmed: 24598541
Am J Hum Genet. 1997 Jul;61(1):101-10
pubmed: 9245990
Am J Hum Genet. 1992 Jul;51(1):10-6
pubmed: 1609789
Neuron. 2011 Oct 20;72(2):245-56
pubmed: 21944778
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4968-77
pubmed: 24248382
Mol Psychiatry. 2016 Aug;21(8):1112-24
pubmed: 26481318
Neuron. 2013 Feb 20;77(4):639-46
pubmed: 23415312
Neurobiol Aging. 2015 Jan;36(1):546.e1-7
pubmed: 25179228
Acta Neuropathol. 2015 Dec;130(6):863-76
pubmed: 26437865
Hum Mol Genet. 2014 Feb 1;23(3):749-54
pubmed: 24057670
Am J Hum Genet. 2013 Mar 7;92(3):345-53
pubmed: 23434116
Hum Mol Genet. 2015 Jun 1;24(11):3133-42
pubmed: 25712133
Am J Hum Genet. 2013 Jun 6;92(6):981-9
pubmed: 23731538
Hum Mol Genet. 2014 Nov 1;23(21):5630-7
pubmed: 24908669
JAMA Neurol. 2017 Apr 1;74(4):445-452
pubmed: 28192553
Acta Neuropathol. 2013 Dec;126(6):881-93
pubmed: 24132570
Neurology. 2018 Jan 23;90(4):e323-e331
pubmed: 29282338
Neurobiol Aging. 2019 Feb;74:234.e1-234.e8
pubmed: 30337192
Acta Neuropathol. 2013 Dec;126(6):829-44
pubmed: 24129584
Acta Neuropathol. 2015 Jan;129(1):39-52
pubmed: 25388784
Lancet Neurol. 2013 Oct;12(10):978-88
pubmed: 24011653
Acta Neuropathol. 2015 May;129(5):715-27
pubmed: 25716178
Science. 2013 Mar 15;339(6125):1335-8
pubmed: 23393093
Acta Neuropathol. 2019 Nov;138(5):795-811
pubmed: 31327044
Acta Neuropathol. 2014 Oct;128(4):525-41
pubmed: 24806409

Auteurs

Jazmyne L Jackson (JL)

Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

NiCole A Finch (NA)

Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Matthew C Baker (MC)

Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Jennifer M Kachergus (JM)

Department of Cancer Biology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Mariely DeJesus-Hernandez (M)

Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Kimberly Pereira (K)

Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Elizabeth Christopher (E)

Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Mercedes Prudencio (M)

Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Michael G Heckman (MG)

Division of Biomedical Statistics and Informatics, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

E Aubrey Thompson (EA)

Department of Cancer Biology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Dennis W Dickson (DW)

Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Jaimin Shah (J)

Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Björn Oskarsson (B)

Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Leonard Petrucelli (L)

Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.

Rosa Rademakers (R)

Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA. Rademakers.Rosa@mayo.edu.

Marka van Blitterswijk (M)

Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA. VanBlitterswijk.Marka@mayo.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH